Results 101 to 110 of about 8,155 (173)

Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefosine on the Toxoplasma gondii RH Strain

Iranian Journal of Parasitology
Background: We aimed to investigate the cytotoxic and apoptotic effects of miltefosine on Toxoplasma gondii RH strain by various techniques. Methods: The study was conducted at the Department of Parasitology and Mycology, Urmia University of Medical ...
Shahram Khademvatan, Elham Yousefi, Negar Asadi, Esmaeil Abasi   +3 more
doaj  

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

, 2007
Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we addressed the question whether miltefosine-resistant Leishmania donovani promastigotes transform to miltefosine-resistant amastigotes.
Croft, Simon L, Pérez-Victoria, F Javier, Castanys, Santiago, Seifert, K., Sánchez-Cañete, María P, Seifert, Karin, Stettler, M., Stettler, Marianne, Croft, S.L., Sánchez-Cañete, María P., Pérez-Victoria, F. J., Gamarro, Francisco   +11 more
core   +1 more source

Oral miltefosine for the treatment of Indian visceral leishmaniasis

, 2006
Large-scale antimony resistance in the treatment of visceral leishmaniasis (VL) in north Bihar, India, has led to the development of miltefosine as an alternative therapy.
Thakur, C. P., Sundar, Shyam, Bhattacharya, S. K., Jha, T. K., Rai, M.   +4 more
core   +1 more source

Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca²⁺ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease

Biomolecules
Originally developed as a chemotherapeutic agent, miltefosine (hexadecylphosphocholine) is an inhibitor of phosphatidylcholine synthesis with proven antiparasitic effects.
Gustavo Benaim, Alberto Paniz-Mondolfi
doaj   +1 more source

Reworking the treatment of Indian Post kala-azar dermal leishmaniasis: A two-step therapy

Journal of Vector Borne Diseases
In the current scenario, treatment of Post kala-azar dermal leishmaniasis (PKDL) is intravenous liposomal amphotericin B or oral miltefosine. Over the years, there has been a gradual decline in the efficacy of miltefosine and a rise in permanent loss of ...
Sushruta Kathuria, Yugansh Gautam, Niti Khunger, Shruti Sharma, Ruchi Singh   +4 more
doaj   +1 more source

Miltefosine Efficiently Eliminates Leishmania major Amastigotes from Infected Murine Dendritic Cells without Altering Their Immune Functions

, 2009
As a treatment for leishmaniasis, miltefosine exerts direct toxic effects on the parasites. Miltefosine also modulates immune cells such as macrophages, leading to parasite elimination via oxidative radicals.
Caroline Gazeau, Esther Von Stebut, Klaus Griewank, Andreas Eichhorn   +3 more
core  

Miltefosine in visceral leishmaniasis.

, 2003
Ridley, Robert G, Olliaro, Piero L, Bryceson, Anthony DM, Engel, Jurgen, Sindermann, Herbert   +4 more
core   +1 more source

Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation. [PDF]

PLoS Negl Trop Dis
Lerona PGE, Jitmuang A, Sarasombath PT, Chayakulkeeree M, Kumlert R, Siriyasatien P, Darby AC, Preativatanyou K.   +7 more
europepmc   +1 more source

Pharmacovigilance in the treatment of cutaneous leishmaniasis: adverse event profile at a reference center. [PDF]

Rev Soc Bras Med Trop
Rezende ALS, Carvalho JP, Noronha BP, Silva SN.   +3 more
europepmc   +1 more source

Optimisation of a Topical Miltefosine Carbopol-Based Gel for Cutaneous Leishmaniasis: Antileishmanial Activity After Storage and Drug Response. [PDF]

Gels
Peña DP, Neira LF, Escobar P.
europepmc   +1 more source